AUTHORS
Subyeta Chowdhury, Amritha Varshini Varshini Hanasoge Hanasoge Somasundara, PhD2, Celina Huang3, Daniel P. Fecko4, Esabella L. Chen5, Ross L. Levine, Prof. Dr.6, Raajit K. Rampal, MD, PhD7
AFFILIATIONS
1 Damon Runyon Cancer Research Foundation, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction:
Aberrant JAK-STAT signaling is the hallmark of myeloproliferative neoplasms (MPN) pathogenesis. JAK inhibitors have demonstrated clear clinical benefits for patients with MPN but are limited in the depth and durability of response they are able to produce in patients. Disease persistence despite JAK inhibition is thought to reflect residual JAK-STAT signaling and activation of parallel pathways, including PI3K/AKT and the MAPK cascade (MEK-ERK). Several mechanisms converge on MEK-ERK activation in myelofibrosis (MF) including PDGFRα activation by PDGF-BB. Recent data also highlights a more direct involvement of the ERK component of this pathway, namely involvement of ERK-pathway components MKNK1 and DUSP6, in MPN pathogenesis. Prior genetic and pharmacologic disruption of ERK1/2 in MPN models have demonstrated enhanced efficacy beyond that observed with ruxolitinib in preclinical models. Ulixertinib (BVD-523) is a novel ERK1/2 inhibitor currently in clinical trials for solid and hematologic malignancies. The goal of this study is to understand the biological effects of the combination of ulixertinib and ruxolitinib in preclinical models of MPN.
Methods:
We performed in vivo efficacy studies using a well-described adoptive transfer murine model of myelofibrosis which produces a lethal phenotype. Briefly, donor bone marrow from Balb/C mice was transduced with hMPLW515L-GFP retrovirus. Bone marrow was then transplanted into lethally-irradiated recipients. Mice were treated with vehicle (VEH), ruxolitinib (RUX), or ruxolitinib plus ulixertinib (RUX+ULI; using two different doses of ULI)) for 4 weeks and terminally sacrificed. Wildtype mice were included as a control. Endpoints included impact of single and doublet therapy on spleen and liver weights, complete blood counts, disease burden (as assessed by GFP in the blood of treated mice), bone marrow LK SLAM progenitor populations by flow cytometry, histopathological analysis, and RNA-sequencing.
Results:
In the hMPLW515L model, RUX+ULI demonstrated superior efficacy compared to RUX alone, with regard to several parameters. At week 4, WBC was significantly reduced (as compared to vehicle treated mice) by RUX (mean WBC 243 K/mL versus 64 K/mL, p<0.01) and RUX+ULI (mean WBC 243 K/mL versus 16 K/mL, p<0.05), but to significantly greater extent by RUX+ULI compared to RUX (p<0.01). Thrombocytosis is characteristic of the hMPLW515L model, and platelet (PLT) count was reduced to a significantly greater extent with RUX+ULI than RUX alone (1053 K/mL versus 2933 K/mL respectively, p<0.05). Peripheral blood GFP positivity was not significantly reduced by RUX as compared to VEH (73% versus 66%, p=0.1) but was significantly reduced by RUX+ULI compared to VEH (73% versus 30%, p<0.01). At the time of terminal sacrifice, spleen weights were not significantly reduced by RUX as compared to VEH (mean of 446 mg versus 364 mg, respectively) but trended lower with RUX+ULI (mean of 317 mg). ULI at a higher dose resulted in lower spleen weights (mean of 203 mg), but the number of samples at this dose were not sufficient for statistical analysis. Analysis of the short-term hematopoietic stem cell population (ST-HSC) demonstrated no difference between VEH and RUX treated mice, but a significant reduction with RUX+ULI compared to VEH treated mice (p<0.05). Overall survival of treated mice did not differ between VEH and RUX arms but was significantly improved with RUX+ULI versus VEH (p<0.05). Spleen and bone marrow pathology assessments will be presented at the meeting for all arms. RNA-sequencing was performed on bone marrow lineage- GFP+ (MPL mutant) and GFP- (WT) populations from all treatment arms to understand the transcriptional effects of combination treatment. These data will be presented at the meeting.
Conclusions:
Ulixertinib in combination with ruxolitinib demonstrates superior disease control in a hMPLW515L model of murine myelofibrosis, improving peripheral blood parameters, disease burden, and overall survival. These findings provide supportive preclinical evidence for a recently initiated phase I/II trial of the combination of RUX+ULI in myelofibrosis patients who have been previously treated with RUX monotherapy but have persistent clinical evidence of disease (NCT06773195). They also provide rationale for additional preclinical studies in MPN genotypes (e.g. RAS-mutant disease) that can further activate MEK-ERK signaling.
DISCLOSURES
Subyeta Chowdhury: No relevant conflicts of interest to declare.